# TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

> **NCT05842785** · PHASE1,PHASE2 · RECRUITING · sponsor: **Tyligand Bioscience (Shanghai) Limited** · enrollment: 162 (estimated)

## Conditions studied

- Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma

## Interventions

- **DRUG:** Phase I dose escalation
- **DRUG:** Phase II-HNSCC
- **DRUG:** Phase II-Advanced melanoma
- **DRUG:** Phase II-solid tumors or lymphomas

## Key facts

- **NCT ID:** NCT05842785
- **Lead sponsor:** Tyligand Bioscience (Shanghai) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-26
- **Primary completion:** 2025-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842785, "TSN222 in Subjects With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05842785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*